Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of oxaliplatin plus bevacizumab salvage chemotherapy in patients with germ cell tumours

Next Previous
Trial Profile

Phase II study of oxaliplatin plus bevacizumab salvage chemotherapy in patients with germ cell tumours

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Oxaliplatin (Primary)
  • Indications Germ cell cancer
  • Focus Therapeutic Use

Most Recent Events

  • 26 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
  • 18 Sep 2014 According to ClinicalTrials.gov record, planned End Date changed from 1 Oct 2013 to 1 Oct 2015.
  • 09 Feb 2012 Planned end date changed from 1 Dec 2012 to 1 Oct 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top